251 related articles for article (PubMed ID: 25982205)
1. Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma.
Mizukoshi E; Nakagawa H; Kitahara M; Yamashita T; Arai K; Sunagozaka H; Fushimi K; Kobayashi E; Kishi H; Muraguchi A; Kaneko S
Cancer Lett; 2015 Aug; 364(2):98-105. PubMed ID: 25982205
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
3. [CTLs induced by hTERT-related multiepitope peptide-sensitived mDCs specifically kill HLA-A24+ tumor cells].
Shen HP; Niu BL; DU HM; Zou LQ; Gong JP
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Jun; 27(6):626-30. PubMed ID: 21651861
[TBL] [Abstract][Full Text] [Related]
4. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
Parkhurst MR; Riley JP; Igarashi T; Li Y; Robbins PF; Rosenberg SA
Clin Cancer Res; 2004 Jul; 10(14):4688-98. PubMed ID: 15269141
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma.
Mizukoshi E; Nakagawa H; Kitahara M; Yamashita T; Arai K; Sunagozaka H; Iida N; Fushimi K; Kaneko S
Cancer Lett; 2015 Dec; 369(1):242-9. PubMed ID: 26325606
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
[TBL] [Abstract][Full Text] [Related]
7. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
[TBL] [Abstract][Full Text] [Related]
8. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
[TBL] [Abstract][Full Text] [Related]
9. Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine.
Niu BL; Du HM; Shen HP; Lian ZR; Li JZ; Lai X; Wei SD; Zou LQ; Gong JP
Vaccine; 2012 May; 30(23):3395-404. PubMed ID: 22480929
[TBL] [Abstract][Full Text] [Related]
10. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
12. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Tsuji H; Yamashita T; Kaneko S
Int J Cancer; 2006 Mar; 118(5):1194-204. PubMed ID: 16152611
[TBL] [Abstract][Full Text] [Related]
13. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice.
Rusakiewicz S; Dosset M; Mollier K; Souque P; Charneau P; Wain-Hobson S; Langlade-Demoyen P; Adotévi O
Vaccine; 2010 Aug; 28(38):6374-81. PubMed ID: 20654669
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients.
Titu LV; Loveday RL; Madden LA; Cawkwell L; Monson JR; Greenman J
Oncol Rep; 2004 Oct; 12(4):871-6. PubMed ID: 15375515
[TBL] [Abstract][Full Text] [Related]
16. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.
Arai J; Yasukawa M; Ohminami H; Kakimoto M; Hasegawa A; Fujita S
Blood; 2001 May; 97(9):2903-7. PubMed ID: 11313288
[TBL] [Abstract][Full Text] [Related]
17. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
Amarnath SM; Dyer CE; Ramesh A; Iwuagwu O; Drew PJ; Greenman J
Int J Oncol; 2004 Jul; 25(1):211-7. PubMed ID: 15202008
[TBL] [Abstract][Full Text] [Related]
18. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes.
Tajima K; Ito Y; Demachi A; Nishida K; Akatsuka Y; Tsujimura K; Hida T; Morishima Y; Kuwano H; Mitsudomi T; Takahashi T; Kuzushima K
Int J Cancer; 2004 Jun; 110(3):403-12. PubMed ID: 15095306
[TBL] [Abstract][Full Text] [Related]
19. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
20. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance.
Domchek SM; Recio A; Mick R; Clark CE; Carpenter EL; Fox KR; DeMichele A; Schuchter LM; Leibowitz MS; Wexler MH; Vance BA; Beatty GL; Veloso E; Feldman MD; Vonderheide RH
Cancer Res; 2007 Nov; 67(21):10546-55. PubMed ID: 17974999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]